Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System

Benzer Materyaller

• Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System
  Yazar:: Maria Antonietta Barbieri, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-10-01)
• Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System
  Yazar:: Giuseppe Cicala, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-09-01)
• Colorectal cancer cells respond differentially to autophagy induced by tyrosine kinase inhibitors
  Yazar:: Lila Louadj, ve diğerleri
  Baskı/Yayın Bilgisi: (2026-04-01)
• Tumor lysis syndrome signal with the combination of encorafenib and binimetinib for malignant melanoma: a pharmacovigilance study using data from the FAERS database
  Yazar:: Shuang Xia, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-09-01)
• Real-world safety profile and mechanistic insights into regorafenib-induced liver failure: a pharmacovigilance study integrated with network toxicology
  Yazar:: Haonan Sun, ve diğerleri
  Baskı/Yayın Bilgisi: (2026-01-01)